Bilirubin, cardiovascular diseases and cancer: epidemiological perspectives

References

• McCarty MF. ‘Iatrogenic Gilbert syndrome’ — a strategy for reducing vascular and cancer risk by increasing plasma unconjugated bilirubin. Med. Hypotheses69(5), 974–994 (2007).
   PubMed Web of Science ®Google Scholar
• Abraham NG, Kappas A. Pharmacological and clinical aspects of hemo oxygenase. Pharmacol. Rev.60(1), 79–127 (2008).
   PubMed Web of Science ®Google Scholar
• Breimer LH, Mikhailidis DP. Could carbon monoxide and bilirubin be friends as well as foes of the body? Scand. J. Clin. Lab. Invest.70(1), 1–5 (2010).
   PubMed Web of Science ®Google Scholar
• Vítek L, Schwertner HA. The heme catabolic pathway and its protective effects on oxidative stress-mediated diseases. Adv. Clin. Chem.43, 1–57 (2007).
   PubMed Web of Science ®Google Scholar
• Schwertner HA, Vítek L. Gilbert syndrome, UGT1A1*28 allele, and cardiovascular disease risk: possible protective effects and therapeutic applications of bilirubin. Atherosclerosis198(1), 1–11 (2008).
   PubMed Web of Science ®Google Scholar
• Vítek L, Ostrow JD. Bilirubin chemistry and metabolism; harmful and protective aspects. Curr. Pharm. Des.15(25), 2869–2883 (2009).
   PubMed Web of Science ®Google Scholar
• Lin JP, Vitek L, Schwertner HA. Serum bilirubin and genes controlling bilirubin concentrations as biomarkers for cardiovascular disease. Clin. Chem.56(10), 1535–1543 (2010).
   PubMed Web of Science ®Google Scholar
• Tolman KG, Rej R. Liver function. In: Tietz Textbook of Clinical Chemistry (3rd Edition). Burtis CA, Ashwood ER (Eds). Saunders, PA, USA 1125–1177 (1999).
   Google Scholar
• Maghzal GJ, Leck MC, Collinson E, Li C, Stocker R. Limited role for the bilirubin-biliverdin redox amplification cycle in the cellular antioxidant protection by biliverdin reductase. J. Biol. Chem.284(43), 29251–29259 (2009).
   PubMed Web of Science ®Google Scholar
• McDonagh AF. The biliverdin–bilirubin antioxidant cycle of cellular protection: missing a wheel? Free Radic. Biol. Med.49(5), 814–820 (2010).
   Google Scholar
• Doumas BT, Kwok-Cheung PP, Perry BW et al. Candidate reference method for determination of total bilirubin in serum: development and validation. Clin. Chem.31(11), 1779–1789 (1985).
   PubMed Web of Science ®Google Scholar
• Madhavan M, Wattigney WA, Srinivasan SR, Berenson GS. Serum bilirubin distribution and its relation to cardiovascular risk in children and young adults. Atherosclerosis131(1), 107–113 (1997).
   PubMed Web of Science ®Google Scholar
• Zucker SD, Horn PS, Sherman KE. Serum bilirubin levels in the U.S. population: gender effect and inverse correlation with colorectal cancer. Hepatology40(8), 827–835 (2004).
   PubMed Web of Science ®Google Scholar
• Ohnaka K, Kono S, Inoguchi T et al. Inverse associations of serum bilirubin with high sensitivity C-reactive protein, glycated hemoglobin, and prevalence of Type 2 diabetes in middle-aged and elderly Japanese men and women. Diabetes Res. Clin. Pract.88(1), 103–110 (2010).
   Google Scholar
• Pocock SJ, Ashby D, Shaper AG, Walker M, Broughton PM. Diurnal variations in serum biochemical and haematological measurements. J. Clin. Pathol.42(2), 172–179 (1989).
   PubMed Web of Science ®Google Scholar
• Fevery J. Fasting hyperbilirubinemia: unraveling the meachmism involved. Gastroenterology113(5), 1798–1800 (1997).
   Google Scholar
• Schwertner HA. Association of smoking and low serum bilirubin antioxidant concentrations. Atherosclerosis136(2), 383–387 (1998).
   PubMed Web of Science ®Google Scholar
• Hayashi S, Omata Y, Sakamoto H et al. Characterization of rat heme oxygenase-3 gene. Implication of processed pseudogenes derived from heme oxygenase-2 gene. Gene336(2), 241–250 (2004).
   PubMedGoogle Scholar
• Exner M, Minar E, Wagner O, Schillinger M. The role of heme oxygenase-1 promoter polymorphisms in human disease. Free Radic. Biol. Med.37(8), 1097–1104 (2004).
   PubMed Web of Science ®Google Scholar
• Yamada N, Yamaya M, Okinaga S et al. Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema. Am. J. Hum. Genet.66(1), 187–195 (2000); erratum in: Am. J. Hum. Genet.68(6), 1542 (2001).
   PubMed Web of Science ®Google Scholar
• Hirai H, Kubo H, Yamaya M et al. Microsatellite polymorphism in heme oxygenase-1 gene promoter is associated with susceptibility to oxidant-induced apoptosis in lymphoblastoid cell lines. Blood102(5), 1619–1621 (2003).
   PubMed Web of Science ®Google Scholar
• Grant DJ, Bell DA. Bilirubin UDP-glucuronosyltransferase 1A1 gene polymorphisms: susceptibility to oxidative damage and cancer? Mol. Carcinog.29(4), 198–204 (2000).
   PubMedGoogle Scholar
• Schwertner HA, Jackson WG, Tolan G. Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin. Chem.40(1), 18–23 (1994).
   PubMed Web of Science ®Google Scholar
• Levinson SS. Relationship between bilirubin, apolipoprotein B, and coronary artery disease. Ann. Clin. Lab. Sci.27(3), 185–192 (1997).
   PubMed Web of Science ®Google Scholar
• Cerne D, Ledinski G, Kager G, Greilberger J, Wang X, Jürgens G. Comparison of laboratory parameters as risk factors for the presence and the extent of coronary or carotid atherosclerosis: the significance of apolipoprotein B to apolipoprotein all ratio. Clin. Chem. Lab. Med.38(6), 529–538 (2000).
   Google Scholar
• Chen YH, Chau LY, Chen JW, Lin SJ. Serum bilirubin and ferritin levels link heme oxygenase-1 gene promoter polymorphism and susceptibility to coronary artery disease in diabetic patients. Diabetes Care31(8), 1615–1620 (2008).
   PubMed Web of Science ®Google Scholar
• Lin R, Wang Y, Wang Y et al. Common variants of four bilirubin metabolism genes and their association with serum bilirubin and coronary artery disease in Chinese Han population. Pharmacogenet. Genomics19(4), 310–318 (2009).
   PubMed Web of Science ®Google Scholar
• Lüblinghoff N, Winkler K, Winkelmann BR et al. Genetic variants of the promoter of the heme oxygenase-1 gene and their influence on cardiovascular disease (the Ludwigshafen Risk and Cardiovascular Health study). BMC Med. Genet.10, 36 (2009).
   Google Scholar
• Ghem C, Sarmento-Leite RE, de Quadros AS, Rossetto S, Gottschall CA. Serum bilirubin concentration in patients with an established coronary artery disease. Int. Heart J.51(2), 86–91 (2010).
   Google Scholar
• Tanaka M, Fukui M, Tomiyasu K et al. Low serum bilirubin concentration is associated with coronary artery calcification (CAC). Atherosclerosis206(1), 287–291 (2009).
   PubMed Web of Science ®Google Scholar
• Endler G, Hamwi A, Sunder-Plassmann R et al. Is low serum bilirubin an independent risk factor for coronary artery disease in men but not in women? Clin. Chem.49(7), 1201–1204 (2003).
   PubMed Web of Science ®Google Scholar
• Hopkins PN, Wu LL, Hunt SC, James BC, Vincent GM, Williams RR. Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. Arterioscler. Thromb. Vasc. Biol.16(2), 250–255 (1996).
   PubMed Web of Science ®Google Scholar
• Hunt SC, Wu LL, Hopkins PN, Williams RR. Evidence for a major gene elevating serum bilirubin concentration in Utah pedigrees. Arterioscler. Thromb. Vasc. Biol.16(8), 912–917 (1996).
   Google Scholar
• Hsieh CJ, Chen MJ, Liao YL, Liao TN. Polymorphisms of the uridine-diphosphoglucuronosyltransferase 1A1 gene and coronary artery disease. Cell. Mol. Biol. Lett.13(1), 1–10 (2008).
   Google Scholar
• Breimer LH, Wannamethee G, Ebrahim S, Shaper AG. Serum bilirubin and risk of ischemic heart disease in middle-aged British men. Clin. Chem.41(10), 1504–1508 (1995).
   PubMed Web of Science ®Google Scholar
• Djoussé L, Levy D, Cupples LA, Evans JC, D’Agostino RB, Ellison RC. Total serum bilirubin and risk of cardiovascular disease in the Framingham offspring study. Am. J. Cardiol.87(10), 1196–1200 (2001).
   PubMed Web of Science ®Google Scholar
• Temme EH, Zhang J, Schouten EG, Kesteloot H. Serum bilirubin and 10-year mortality risk in a Belgian population. Cancer Causes Control12(10), 887–894 (2001).
   PubMed Web of Science ®Google Scholar
• Bosma PJ, van der Meer IM, Bakker CT, Hofman A, Paul-Abrahamse M, Witteman JC. UGT1A1*28 allele and coronary heart disease: the Rotterdam Study. Clin. Chem.49(7), 1180–1181 (2003).
   PubMed Web of Science ®Google Scholar
• Troughton JA, Woodside JV, Young IS et al. Bilirubin and coronary heart disease risk in the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Eur. J. Cardiovasc. Prev. Rehabil.14(1), 79–84 (2007).
   PubMed Web of Science ®Google Scholar
• Ekblom K, Marklund SL, Jansson JH et al. Plasma bilirubin and UGT1A1*28 are not protective factors against first-time myocardial infarction in a prospective, nested case-referent setting. Circ. Cardiovasc. Genet.3(4), 340–347 (2010).
   PubMed Web of Science ®Google Scholar
• Schwertner HA. Bilirubin concentration, UGT1A1*28 polymorphism, and coronary artery disease. Clin. Chem.49(7), 1039–1040 (2003).
   PubMed Web of Science ®Google Scholar
• Breimer LH, Mikhailidis DP. Bilirubin and peripheral arterial disease: 15 years later. Expert Opin. Ther. Targets13(2), 139–140 (2009).
   PubMed Web of Science ®Google Scholar
• Vítek L, Jirsa M, Brodanova M et al. Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis160(2), 449–456 (2002).
   PubMed Web of Science ®Google Scholar
• Perlstein TS, Pande RL, Creager MA, Weuve J, Beckman JA. Serum total bilirubin level, prevalent stroke, and stroke outcomes: NHANES 1999–2004. Am. J. Med.121(9), 781–788 (2008).
   PubMed Web of Science ®Google Scholar
• Kimm H, Yun JE, Jo J, Jee SH. Low serum bilirubin level as an independent predictor of stroke incidence: a prospective study in Korean men and women. Stroke40(11), 3422–3427 (2009).
   PubMed Web of Science ®Google Scholar
• Nieto FJ, Iribarren C, Gross MD, Comstock GW, Cutler RG. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis148(1), 131–139 (2000).
   PubMed Web of Science ®Google Scholar
• Ishizaka N, Ishizaka Y, Takahashi E, Yamakado M, Hashimoto H. High serum bilirubin level is inversely associated with the presence of carotid plaque. Stroke32(2), 580–583 (2001).
   PubMedGoogle Scholar
• Ishizaka N, Ishizaka Y, Toda E, Nagai R, Yamakado M. Association between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Japanese individuals. Arterioscler. Thromb. Vasc. Biol.25(5), 1038–1044 (2005).
   PubMed Web of Science ®Google Scholar
• Erdogan D, Gullu H, Yildirim E et al. Low serum bilirubin levels are independently and inversely related to impaired flow-mediated vasodilation and increased carotid intima-media thickness in both men and women. Atherosclerosis184(2), 431–437 (2006).
   PubMed Web of Science ®Google Scholar
• Vítek L, Novotný L, Sperl M, Holaj R, Spácil J. The inverse association of elevated serum bilirubin levels with subclinical carotid atherosclerosis. Cerebrovasc. Dis.21(5–6), 408–414 (2006).
   PubMed Web of Science ®Google Scholar
• Yang XF, Chen YZ, Su JL, Wang FY, Wang LX. Relationship between serum bilirubin and carotid atherosclerosis in hypertensive patients. Intern. Med.48(18), 1595–1599 (2009).
   Google Scholar
• Breimer LH, Spyropolous KA, Winder AF, Mikhailidis DP, Hamilton G. Is bilirubin protective against coronary artery disease? Clin. Chem.40(10), 1987–1988 (1994).
   PubMedGoogle Scholar
• Perlstein TS, Pande RL, Beckman JA, Creager MA. Serum total bilirubin level and prevalent lower-extremity peripheral arterial disease: National Health and Nutrition Examination Survey (NHANES) 1999 to 2004. Arterioscler. Thromb. Vasc. Biol.28(1), 166–172 (2008).
   PubMed Web of Science ®Google Scholar
• Rantner B, Kollerits B, Anderwald-Stadler M et al. Association between the UGT1A1 TA-repeat polymorphism and bilirubin concentration in patients with intermittent claudication: results from the CAVASIC study. Clin. Chem.54(5), 851–857 (2008).
   PubMed Web of Science ®Google Scholar
• Bhuiyan AR, Srinivasan SR, Chen W, Sultana A, Berenson GS. Association of serum bilirubin with pulsatile arterial function in asymptomatic young adults: the Bogalusa Heart Study. Metabolism57(5), 612–616 (2008).
   Google Scholar
• Chen YH, Lin SJ, Lin MW et al. Microsatellite polymorphism in promoter of heme oxygenase-1 gene is associated with susceptibility to coronary artery disease in Type 2 diabetic patients. Hum. Genet.111(1), 1–8 (2002).
   PubMed Web of Science ®Google Scholar
• Kaneda H, Ohno M, Taguchi J et al. Heme oxygenase-1 gene promoter polymorphism is associated with coronary artery disease in Japanese patients with coronary risk factors. Arterioscler. Thromb. Vasc. Biol.22(10), 1680–1685 (2002).
   PubMed Web of Science ®Google Scholar
• Endler G, Exner M, Schillinger M et al. A microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with increased bilirubin and HDL levels but not with coronary artery disease. Thromb. Haemost.91(1), 155–161 (2004).
   Google Scholar
• Ono K, Goto Y, Takagi S et al. A promoter variant of the heme oxygenase-1 gene may reduce the incidence of ischemic heart disease in Japanese. Atherosclerosis173(2), 315–319 (2004).
   PubMed Web of Science ®Google Scholar
• Lin JP, O’Donnell CJ, Schwaiger JP et al. Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation114(14), 1476–1481 (2006).
   PubMed Web of Science ®Google Scholar
• Kronenberg F. Associataion of bilirubin with cardiovascular outcomes. More hype than substance. Circ. Cardiovasc. Genet.3(4), 308–310 (2010).
   Google Scholar
• Lingenhel A, Kollerits B, Schwaiger JP et al. Serum bilirubin levels, UGT1A1 polymorphisms and risk for coronary artery disease. Exp. Gerontol.43(12), 1102–1107 (2008).
   PubMedGoogle Scholar
• Gajdos V, Petit FM, Perret C et al. Further evidence that the UGT1A1*28 allele is not associated with coronary heart disease: the ECTIM study. Clin. Chem.52(12), 2313–2314 (2006).
   PubMed Web of Science ®Google Scholar
• Breimer LH. Molecular mechanisms of oxygen radical carcinogenesis and mutagenesis: the role of DNA base damage. Mol. Carcinog.3(4), 188–197 (1990).
   PubMed Web of Science ®Google Scholar
• Breimer LH. Repair of DNA damage induced by reactive oxygen species. Free Radic. Res. Commun.14(3), 159–171 (1991).
   PubMed Web of Science ®Google Scholar
• Ko WF, Helzlsouer KJ, Comstock GW. Serum albumin, bilirubin, and uric acid and the anatomic site-specific incidence of colon cancer. J. Natl Cancer Inst.86(24), 1874–1875 (1994).
   PubMedGoogle Scholar
• Ioannou GN, Liou IW, Weiss NS. Serum bilirubin and colorectal cancer risk: a population-based cohort study. Aliment. Pharmacol. Ther.23(11), 1637–1642 (2006).
   Google Scholar
• Ching S, Ingram D, Hahnel R, Beilby J, Rossi E. Serum levels of micronutrients, antioxidants and total antioxidant status predict risk of breast cancer in a case control study. J. Nutr.132(2), 303–306 (2002).
   PubMed Web of Science ®Google Scholar
• Vítek L. Bilirubin and colorectal cancer. Aliment. Pharmacol. Ther.24(10), 1503–1504 (2006).
   Google Scholar
• Ioannou GN, Liou IW, Weiss NS. Serum bilirubin and colorectal cancer risk: authors’ reply. Aliment. Pharmacol. Ther.23(10), 1504 (2006).
   Google Scholar
• Chang KW, Lee TC, Yeh WI et al. Polymorphism in heme oxygenase-1 (HO-1) promoter is related to the risk of oral squamous cell carcinoma occurring on male areca chewers. Br. J. Cancer.91(8), 1551–1555 (2004).
   PubMed Web of Science ®Google Scholar
• Hu JL, Li ZY, Liu W et al. Polymorphism in heme oxygenase-1 (HO-1) promoter and alcohol are related to the risk of esophageal squamous cell carcinoma on Chinese males. Neoplasma57(1), 86–92 (2010).
   PubMed Web of Science ®Google Scholar
• Kikuchi A, Yamaya M, Suzuki S et al. Association of susceptibility to the development of lung adenocarcinoma with the heme oxygenase-1 gene promoter polymorphism. Hum. Genet.116(5), 354–360 (2005).
   Google Scholar
• Lo SS, Lin SC, Wu CW et al. Heme oxygenase-1 gene promoter polymorphism is associated with risk of gastric adenocarcinoma and lymphovascular tumor invasion. Ann. Surg. Oncol.14(8), 2250–2256 (2007).
   Google Scholar
• Sawa T, Mounawar M, Tatemichi M, Gilibert I, Katoh T, Ohshima H. Increased risk of gastric cancer in Japanese subjects is associated with microsatellite polymorphisms in the heme oxygenase-1 and the inducible nitric oxide synthase gene promoters. Cancer Lett.269(1), 78–84 (2008).
   Google Scholar
• Okamoto I, Krögler J, Endler G et al. A microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with risk for melanoma. Int. J. Cancer119(6), 1312–1315 (2006).
   PubMed Web of Science ®Google Scholar
• Hong CC, Ambrosone CB, Ahn J et al. Genetic variability in iron-related oxidative stress pathways (Nrf2, NQO1, NOS3, and HO-1), iron intake, and risk of postmenopausal breast cancer. Cancer Epidemiol. Biomarkers Prev.16(9), 1784–1794 (2007).
   PubMed Web of Science ®Google Scholar
• Fang JL, Lazarus P. Correlation between the UDP-glucuronosyltransferase (UGT1A1) TATAA box polymorphism and carcinogen detoxification phenotype: significantly decreased glucuronidating activity against benzo(a)pyrene-7,8-dihydrodiol(-) in liver microsomes from subjects with the UGT1A1*28 variant. Cancer Epidemiol. Biomarkers Prev.13(1), 102–109 (2004).
   PubMed Web of Science ®Google Scholar
• Girard H, Thibaudeau J, Court MH et al.UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver. Hepatology42(2), 448–457 (2005).
   PubMed Web of Science ®Google Scholar
• Chang JL, Bigler J, Schwarz Y et al.UGT1A1 polymorphism is associated with serum bilirubin concentrations in a randomized, controlled, fruit and vegetable feeding trial. J. Nutr.137(4), 890–897 (2007).
   PubMedGoogle Scholar
• van der Logt EM, Bergevoet SM, Roelofs HM et al. Genetic polymorphisms in UDP-glucuronosyltransferases and glutathione S-transferases and colorectal cancer risk. Carcinogenesis25(12), 2407–2415. (2004).
   PubMed Web of Science ®Google Scholar
• Girard H, Butler LM, Villeneuve L et al.UGT1A1 and UGT1A9 functional variants, meat intake, and colon cancer, among Caucasians and African–Americans. Mutat. Res.644(1–2), 56–63 (2008).
   PubMed Web of Science ®Google Scholar
• Tang KS, Chiu HF, Chen HH et al. Link between colorectal cancer and polymorphisms in the uridine-diphosphoglucuronosyltransferase 1A7 and 1A1 genes. World J. Gastroenterol.11(21), 3250–3254 (2005).
   PubMed Web of Science ®Google Scholar
• Lacko M, Roelofs HM, Te Morsche RH et al. Genetic polymorphism in the conjugating enzyme UGT1A1 and the risk of head and neck cancer. Int. J. Cancer DOI: 10.1002/ijc.25296 (2010) (Epub ahead of print).
   Google Scholar
• Guillemette C, Millikan RC, Newman B, Housman D. Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans. Cancer Res.60(4), 950–956 (2000).
   PubMed Web of Science ®Google Scholar
• Huo D, Kim HJ, Adebamowo CA et al. Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and breast cancer risk in Africans. Breast Cancer Res. Treat.110(2), 367–376 (2008).
   PubMed Web of Science ®Google Scholar
• Guillemette C, De Vivo I, Hankinson SE et al. Association of genetic polymorphisms in UGT1A1 with breast cancer and plasma hormone levels. Cancer Epidemiol. Biomarkers Prev.10(6), 711–714 (2001).
   PubMed Web of Science ®Google Scholar
• MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk. Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women. Breast Cancer Res. Treat.119(2), 463–474 (2010); erratum in Breast Cancer Res. Treat.119(2), 475 (2010).
   PubMed Web of Science ®Google Scholar
• Adegoke OJ, Shu XO, Gao YT et al. Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 (UGT1A1) and risk of breast cancer. Breast Cancer Res. Treat.85(3), 239–245 (2004).
   PubMed Web of Science ®Google Scholar
• Duguay Y, McGrath M, Lépine J et al. The functional UGT1A1 promoter polymorphism decreases endometrial cancer risk. Cancer Res.64(3), 1202–1207 (2004).
   PubMed Web of Science ®Google Scholar
• Rebbeck TR, Troxel AB, Wang Y et al. Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk. J. Natl Cancer Inst.98(18), 1311–1320 (2006).
   PubMedGoogle Scholar
• Deming SL, Zheng W, Xu WH et al.UGT1A1 genetic polymorphisms, endogenous estrogen exposure, soy food intake, and endometrial cancer risk. Cancer Epidemiol. Biomarkers Prev.17(3), 563–570 (2008).
   PubMed Web of Science ®Google Scholar
• Holt SK, Rossing MA, Malone KE, Schwartz SM, Weiss NS, Chen C. Ovarian cancer risk and polymorphisms involved in estrogen catabolism. Cancer Epidemiol. Biomarkers Prev.16(3), 481–489 (2007).
   PubMed Web of Science ®Google Scholar
• Karatzas A, Giannatou E, Tzortzis V et al. Genetic polymorphisms in the UDP-glucuronosyltransferase 1A1 (UGT1A1) gene and prostate cancer risk in Caucasian men. Cancer Epidemiol.34(3), 345–349 (2010).
   PubMed Web of Science ®Google Scholar
• Fulks M, Stout RL, Dolan VF. Mortality associated with bilirubin levels in insurance applicants. J. Insur. Med.41(3), 49–53 (2009).
   PubMedGoogle Scholar
• Breimer LH. Mortality associated with bilirubin levels. J. Insur. Med.41(3), 230–231 (2009).
   Google Scholar
• Inoguchi T, Sasaki S, Kobayashi K, Takayanagi R, Yamada T. Relationship between Gilbert syndrome and prevalence of vascular complications in patients with diabetes. JAMA298(12), 1398–1400 (2007).
   PubMed Web of Science ®Google Scholar
• Davey Smith G, Ebrahim S. ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int. J. Epidemiol.32(1), 1–22 (2003).
   PubMed Web of Science ®Google Scholar
• Jiraskova A, Lenicek M, Vitek L. Simultaneous genotyping of microsatellite variations in HMOX1 and UGT1A1 genes using multicolored capillary electrophoresis. Clin. Biochem.43(7–8), 697–699 (2010).
   Google Scholar
• Vítek L, Muchová L, Jančová E et al. Association of systemic lupus erythematosus with low serum bilirubin levels. Scand. J. Rheumatol. (2010) DOI: 10.3109/03009741003742748 (Epub ahead of print).
   Google Scholar
• Vítek L, Leníček M, Jirsa M et al. Serum bilirubin levels and UGT1A1 promoter variations in patients with schizophrenia. Psychiatry Res.178(2), 449–450 (2010).
   Google Scholar